What are peptides? A UK guide to the science, evidence and safety

Peptides are chains of amino acids. Some are essential signals in the body, and some have become effective medicines. Others are cosmetic ingredients, food supplements or experimental substances. The word peptide tells you something about a molecule’s structure. It does not tell you whether a particular product is effective, suitable for you or authorised for medical use.

This guide explains what peptides do, how to interpret studies and which UK regulatory questions matter. It does not provide a protocol for self-use or suggest that medical supervision, a laboratory certificate or blood tests can make an experimental product safe.

1. What is a peptide, and how is it different from a protein?

Amino acids are small molecules that can join together through chemical links called peptide bonds. A chain of them is a peptide. Longer chains are often called polypeptides; proteins consist of one or more chains folded into structures that allow them to perform particular jobs. The National Human Genome Research Institute’s definition uses approximately 2–50 amino acids for a short peptide. That is a useful introductory convention, not a safety boundary.

The important features are not just the number of amino acids. Their order, the molecule’s shape and chemical modifications affect how it behaves. Two products described as “peptides” can therefore act differently, just as two medicines can have entirely different uses and risks.

“Natural” and “synthetic” are also incomplete descriptions. A naturally occurring molecule can have powerful effects. A manufactured medicine can be well characterised and useful. What matters clinically is the exact preparation, exposure, evidence and person receiving it.

2. How do peptides work in the body?

Some peptides act as signals. A signal binds to a receptor—a structure on or within a cell that recognises it—and changes cellular activity. A drug that activates a receptor is called an agonist. Not every peptide works through the same receptor, and not every peptide has a useful therapeutic action.

Insulin illustrates why the category matters in medicine: it is a hormone that helps glucose enter cells, as explained by the US National Institute of Diabetes and Digestive and Kidney Diseases. Semaglutide is a different molecule that activates GLP-1 receptors. Its UK product information describes effects on glucose regulation and other physiological processes. These are different actions, not interchangeable versions of “peptide treatment”.

A biological mechanism is the beginning of an explanation. It is not proof of a patient benefit. Activating a pathway associated with tissue repair does not establish that an injured person recovers faster. Raising a hormone concentration does not establish better strength, health or longevity.

The body’s own signals also operate within feedback systems. Adding a substance from outside the body changes the context: where it reaches, how much reaches it and how long the exposure lasts all matter. A claim that something “already exists in your body” leaves those questions unanswered.

3. Five different things can be sold or discussed as peptides

These categories need to be separated before comparing benefits or risks. A useful first question is: am I reading about a finished medicine, a cosmetic, a food, a clinical-trial product or a research chemical?

The NHS describes established insulin treatment, while the MHRA lists licensed GLP-1 products and their different uses. Those examples show that peptide medicines can have an established role. They do not validate every other peptide, or every product using the same ingredient name.

Cosmetics and food supplements have their own requirements. Great Britain’s cosmetic guidance requires a safety assessment for the cosmetic product. Food-claim rules do not permit claims that a food treats, prevents or cures disease. Neither category provides a shortcut to authorisation as a medicine.

4. Why a cream, tablet, nasal spray and injection are not equivalent

The route changes what a substance encounters before it reaches a potential target. A topical product must work in its intended skin context. A swallowed product encounters digestive enzymes and barriers to absorption. An injection changes those barriers but introduces a different set of formulation, sterility and administration questions.

Bioavailability means the proportion of a dose that reaches the circulation in an available form. A high amount on a label does not tell you that proportion. Nor does greater exposure automatically mean greater benefit.

A useful counterexample to the claim that “peptides cannot work orally” is oral semaglutide. Buckley and colleagues’ 2018 research examined a formulation containing an absorption enhancer, SNAC, using clinical and preclinical work. Absorption involved the stomach and depended on the formulation. This supports a specific delivery approach; it does not establish that any peptide powder put in a capsule will work.

Likewise, a study of a skincare preparation cannot establish the safety of injecting its ingredient. A different route, formulation or concentration creates a different evidence question. Nasal delivery is also a route to assess, not a guarantee of safety simply because it avoids a needle.

For a prescribed medicine, follow its own instructions. Do not change the route, crush a preparation or substitute a research product on the assumption that the ingredient name makes them equivalent.

5. What counts as evidence that a peptide works?

The useful question is specific: did this defined intervention improve this outcome in these people, compared with an appropriate alternative, over a meaningful period? “Research-backed” is too vague to answer it.

The NHS explains the phases of medicine trials. Early trials often focus on tolerability and what the body does with a substance. Later studies investigate benefits and harms in relevant patient groups. A phase number is useful context, but it is not an approval certificate or a substitute for reading the result.

Check whether the endpoint matters to patients. A blood marker, image or laboratory measurement can be informative without proving less pain, fewer injuries or a longer life. Also check who was excluded, how many people stopped treatment and whether follow-up was long enough for the question.

Three phrases should stay separate: no evidence of benefit, evidence of no benefit and not enough evidence to decide. The first may reflect missing research. The second requires research capable of answering the question. The third describes uncertainty rather than a positive or negative verdict.

6. Three examples of how to read peptide claims

BPC-157: a small safety report is not an established treatment

A 2025 pilot report by Lee and Burgess described two adults who had already received intravenous BPC-157 before the study. The researchers assessed selected blood markers and vital signs over three days and reported no side effects. There was no comparison group.

Our interpretation: this is a very small observation, not reliable reassurance about uncommon harms, repeated use or other populations. It also did not test whether BPC-157 heals a tendon or treats gut disease. A title containing the word “safety” cannot answer questions the design did not investigate. BPC-157 is specifically listed under non-approved substances in the 2026 WADA Prohibited List.

CJC-1295: a hormone result is not a recovery result

Teichman and colleagues’ 2006 paper reported two randomised, placebo-controlled studies lasting 28 and 49 days in healthy adults. CJC-1295 increased growth hormone and IGF-I concentrations; those hormone measures were central outcomes.

Our interpretation: the studies demonstrate biological activity under their conditions. They do not establish faster injury recovery, an anti-ageing benefit or long-term safety for people using online products. A controlled trial can be real and still be the wrong evidence for a particular marketing claim.

Retatrutide: clinical development does not authorise online products

Retatrutide illustrates a different issue: a medicine can be undergoing substantial clinical development while remaining investigational. On 24 July 2026, the MHRA stated that retatrutide had not been authorised for UK use and warned about online products sold under its name. Lilly’s September 2026 update continued to describe it as investigational and not approved by any regulator. The developer is a primary source for its programme’s status, not independent evidence of a favourable benefit–risk balance.

A study using a controlled research preparation does not establish the contents or quality of a separately purchased vial. Positive results and regulatory authorisation are distinct events; neither should be predicted from a seller’s timetable. Check current official status rather than relying on an old news story.

7. What do licensed, off-label, unlicensed and investigational mean in the UK?

These words answer different questions. Confusing them can make an experimental product sound like a routine prescription medicine.

MHRA guidance on prescribing responsibilities explains that off-label or unlicensed use can require greater responsibility from the prescriber. Evidence, patient need, informed discussion and ongoing care matter. A prescription is a clinical decision, not a device for converting an unsupported claim into an established treatment.

The MHRA’s specials guidance describes the exemption under Regulation 167 of the Human Medicines Regulations 2012 for individual patient needs that cannot be met by an available licensed medicine. Relevant conditions apply to supply, manufacture and import. It is inaccurate to call every research peptide a “special” merely because it is unlicensed.

Does “research use only” settle the law?

No. Under the MHRA’s product-classification guidance, the presentation, claims, properties and intended use matter. A disclaimer does not override the product’s actual context. Equally, “all peptides are illegal” is inaccurate: the category includes authorised medicines and products governed by other rules.

Approval abroad is not a substitute for the applicable UK authorisation. Questions about possession, advertising, import and supply are also different legal questions. A statement about one should not be used as reassurance about the others.

How can a reader check an approval claim?

1. Identify the exact finished product, manufacturer, formulation and claimed use.
2. Look for its current patient leaflet or summary of product characteristics in the MHRA products service.
3. Check that the authorised indication matches the claim—not just that the ingredient name appears somewhere.
4. If anything is unclear, ask a registered healthcare professional to interpret the status. A seller’s screenshot or an unsuccessful search alone is not a complete regulatory assessment.

UK restrictions also apply to promotion: MHRA advertising guidance prohibits public advertising of prescription-only medicines and advertising unauthorised medicines. This guide provides information, without a research-peptide sales or prescribing offer.

8. What are the risks and side effects?

There is no meaningful universal list of “peptide side effects”. Risks depend on the substance, formulation, route, exposure and individual. Combining every possible harm into one list would be misleading; presenting the whole category as safe would be equally misleading.

For an authorised medicine, known adverse effects and precautions belong in its patient leaflet and product information. For experimental products, important risks may not have been measured well enough to estimate their frequency. “No side effects reported” and “no side effects possible” are very different statements.

The MHRA’s warning about unauthorised weight-loss products illustrates the distinction between an ingredient being researched and the contents of products sold online. This is a product-quality problem as well as an evidence problem.

Does a certificate of analysis prove safety?

A certificate can provide information about a tested sample, depending on the methods and the report’s authenticity. It cannot answer questions that were not tested. Identity, chemical purity, quantity, sterility and clinical effectiveness are separate questions.

For example, an identity test may indicate that a sample contains a named compound. It does not establish that the finished preparation is sterile, that it was stored correctly or that administering it benefits a patient. Even a technically sound laboratory report cannot replace clinical evidence and the applicable regulatory requirements.

Who needs particular caution?

There is no validated self-use eligibility checklist for experimental research peptides. People who are pregnant, breastfeeding, under 18, taking several medicines or living with significant illness should not interpret the absence of a listed warning as evidence that a product is suitable. Missing research leaves uncertainty.

This is not advice to stop an authorised prescribed medicine. People using established treatments need advice specific to that medicine and their circumstances. For example, the MHRA’s GLP-1 guidance includes specific pregnancy and breastfeeding precautions; those instructions should not be generalised to every peptide medicine.

9. Can blood tests or monitoring make research-peptide use safe?

No blood panel can certify an experimental peptide as safe. Blood tests can help answer a clinical question, such as investigating symptoms or monitoring a particular treatment. The NHS blood-test guide explains these diagnostic and monitoring roles.

The limit follows from what is measured: a result describes selected markers at a particular time. It does not identify the contents of a vial, establish sterility, prove benefit or exclude harms that those markers do not detect. An abnormal result also needs interpretation; it should not automatically be attributed to a peptide.

A clinician may reasonably investigate someone who has already used a product. That is different from offering a normal set of results as clearance to start or continue it. Persistent or worsening symptoms need assessment even when previous tests were normal.

10. What should athletes know?

Medical authorisation and permission in sport are separate questions. Under the WADA list in force for 2026, BPC-157 is prohibited at all times under S0. CJC-1295, ipamorelin, and thymosin-β4 and derivatives such as TB-500 are covered by S2 and prohibited at all times. These examples are not the whole list.

UK Anti-Doping explains athletes’ responsibility to check medicines, including prescribed ones. A prescription does not automatically remove an anti-doping restriction. Use the current checking and therapeutic-use-exemption guidance, and tell the treating professional that you are subject to anti-doping rules.

If a product is missing from a search, do not assume it is permitted. Seek clarification through UKAD. Rules and lists change; an old article or advice from a teammate is not a sufficient check. Emergency treatment should not be delayed while making an anti-doping enquiry.

11. If you have already used a research peptide

Be open with a healthcare professional. Bring the packaging or a photograph, product name, route used, dates of use, any symptoms and a list of other medicines or supplements. Say when the identity or amount is uncertain. That uncertainty helps the assessment; it is not a reason to avoid asking for help.

Do not add another substance to manage an unexplained symptom or rely on a seller’s reassurance. If you inject non-prescribed products, do not share or reuse injecting equipment; local harm-reduction services can advise on infection prevention and appropriate care. UK public-health guidance for services supporting image and performance enhancing drug users emphasises access to appropriate support. Such support reduces particular harms; it does not establish that the substance is safe.

Suspected medicine side effects and product concerns can also be reported through the MHRA Yellow Card scheme. Reporting is not a substitute for medical care, and a report does not by itself prove what caused a reaction.

12. How a pharmacist approaches a peptide claim

A useful assessment starts with the person’s problem and the evidence needed to answer it. “Which peptide is best?” skips too many steps.

1. Define the concern. Is this an injury, persistent symptom, diagnosed condition or appearance-related goal?
2. Identify the intervention. Establish the exact substance, formulation, route and source. Similar names are not enough.
3. Match the evidence. Look for research in the relevant population, using the relevant preparation and a meaningful outcome.
4. Check status and risks. Consider authorisation, uncertainty, other medicines, medical history and sporting rules where relevant.
5. Compare appropriate options. Include established assessment and treatment, rather than comparing experimental products only with each other.
6. Explain what cannot be concluded. A responsible answer may be that there is insufficient evidence to recommend a proposed use.

For example, recurring tendon pain calls for assessment and a rehabilitation plan appropriate to the diagnosis. Persistent digestive symptoms need their cause considered. A weight-management question needs an assessment of suitable established options. A peptide claim should not replace those steps.

Puri Pharmacy’s position: this resource is intended to help readers understand the science, identify misleading claims and have informed conversations. We do not offer the experimental research peptides discussed here. There is no supplier recommendation, self-injection protocol or testing package presented as a way to make their use safe.

Questions readers ask

Are peptides the same as steroids?

No. They are different chemical categories. That distinction does not make every peptide safe or permitted in sport: anti-doping restrictions cover several classes of substances.

Are all peptides hormones?

No. Some peptides act as hormones, but “peptide” describes a chemical structure and “hormone” describes a signalling role. The terms are not interchangeable.

Is a “peptide stack” supported if its ingredients have separate studies?

Not necessarily. Studies of individual substances do not establish the effects, interactions or safety of the combination. A blend is a further evidence question, not the sum of advertised benefits.

Can a licensed peptide medicine be safe for everyone?

No. Authorisation concerns defined uses and an assessed balance of benefit and risk. Suitability still depends on the medicine and individual; warnings and contraindications remain relevant.

Does a study listed on PubMed mean the NHS endorses the treatment?

No. PubMed indexes research. Inclusion does not mean the study’s conclusions are correct, that the NHS recommends the intervention or that a UK medicine authorisation exists.

What would change a cautious assessment?

Relevant, well-conducted human research could change confidence about a specific benefit or harm. Regulatory decisions could change a product’s authorised status. Neither would automatically validate unrelated online products or every proposed use.

Evidence summary

• What human evidence shows: some peptide medicines have established clinical uses; evidence for experimental products varies substantially.
• What is not established: shared chemistry does not give every product the benefits or safety record of a licensed medicine.
• Main safety uncertainties: the exact preparation, route, quality, exposure and patient context can change the assessment.
• What would change the assessment: relevant controlled human results, reliable harm data and current regulatory decisions for a defined use.

Ask Rahul

Rahul Puri | Pharmacist

Peptide evidence, safety and UK regulation

How should we approach a promising peptide?

I want readers to understand both the strongest finding in favour of a peptide and the limit of that finding. A positive human trial deserves attention; so does a negative result. My assessment changes when the evidence changes, but the evidence must match the substance, route, person and outcome being discussed.

Retatrutide is a useful example: promising clinical results can justify interest without justifying an online purchase. Read my retatrutide evidence and UK safety analysis for a worked example.

Follow the evidence with Rahul

1. Use the evidence checklist to examine a claim.
2. Check the UK regulatory distinctions and the remaining safety questions.
3. Subscribe to Puri’s health updates, including peptide analysis.

Follow Rahul’s peptide analysis

Subscribe to Puri Pharmacy’s health updates, including Rahul Puri’s explanations of peptide evidence, safety and UK regulation. This is an educational newsletter, not access to peptide treatment.

Email addressSubscribe to health updates

By subscribing, you agree to receive Puri Pharmacy’s health emails. Read our privacy policy.

Have a study you would like explained? Send its link through our contact form. This is an educational enquiry route, not access to an experimental peptide. For urgent symptoms, seek urgent medical care directly.